Raymond James Financial
ABUS icon

Raymond James Financial’s Arbutus Biopharma ABUS Stock Holding History

Raymond James Financial’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$861K Buy
191,355
+131,170
+218% +$574K ﹤0.01% 3968
2025
Q4 		$289K Buy
+60,185
New +$271K ﹤0.01% 4599
2025
Q3 		– Sell
-8,504
Closed -$26.3K – 4965
2025
Q2 		$26.3K Sell
8,504
-2,000
-19% -$6.64K ﹤0.01% 5475
2025
Q1 		$36.7K Hold
10,504
– – ﹤0.01% 4665
2024
Q4 		$34.3K Buy
+10,504
New +$38.6K ﹤0.01% 4660

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Raymond James Financial's ABUS Position: Q1 2026 in Review

Raymond James Financial increased its Arbutus Biopharma (ABUS) stake by 218% in Q1 2026, buying an estimated $574K and bringing the position to 191,355 shares worth $861K. The position accounts for ﹤0.01% of the portfolio, ranked #3968.

Raymond James Financial first reported a position in ABUS in Q4 2024 and has held it in 5 quarters since. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Raymond James Financial held 191,355 shares of Arbutus Biopharma worth $861K as of Q1 2026.
  • Raymond James Financial bought 131,170 Arbutus Biopharma shares in Q1 2026, an estimated $574K.
  • Arbutus Biopharma made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3968 holding.
  • Raymond James Financial first reported a position in Arbutus Biopharma in Q4 2024 and has held it in 5 quarters since.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.